Thought leaders in vaccines, DNA vaccines and electroporation

David B. Weiner, Ph.D.

Chairman, Inovio Scientific Advisory Board
Professor, Dept. of Pathology & Laboratory Medicine, University of Pennsylvania

Chair, Gene Therapy and Vaccine Program, CAMB
University of Pennsylvania Perelman School of Medicine

DAVID B. WEINER is a world-renowned leader in immunology as well as gene vaccines and therapy. As a pioneer in the field of DNA vaccines, he has over 300 peer-reviewed publications in scientific journals to his credit, including publication in mainstream scientific journals such as Scientific American, and has been noted by the Institute for Scientific Information as one of the top cited scientists in the world. He was also the editor of several published works including: Biologically active Peptides: Design, Synthesis and Utilization, by David B. Weiner and William V. Willams; Vaccine Special Issue: DNA Vaccine Meeting 2010, DNA Vaccines - Vaccine Special Volume 2006; DNA Vaccines: Research Frontiers and Clinical Applications, Vaccine Special Volume 2004; and Expert Review of Vaccines: AIDS Vaccines, August 2004, among others.

Dr. Weiner serves and has served as an advisor to and collaborator with leading companies such as Pfizer (Wyeth), 3M, J&J (Centocor), and GSK. He played a key role in the start-up of biotechnology companies such as Apollon (one of the world's first DNA vaccine companies), Synbiotics, Immune Pharmaceutics, Verigen, and Symphony Pharmaceutics. He is a special employee and advisor for FDA/CBER and the NIH-NIAID-DAIDS Grant Review process.

Dr. Weiner co-founded VGX Pharmaceuticals, which merged with Inovio Pharmaceuticals in June 2009.

 

Thomas S. Edgington, M.D.

Emeritus Professor
Scripps Research Institute

THOMAS EDGINGTON, is a world leader in immunology and microbial research. His research focus has long been the molecular identification, pathways and structural biology of the molecules constituting the pathogenetic mechanisms of major diseases particularly those that involve vascular biology. He has over 500 publications in the biomedical sciences and filed over 25 patents.

A member of the U.S. National Academy of Sciences and the Institute of Medicine, Dr. Edgington served as the president and a board member of the Federation of American Societies for Experimental Biology (FASEB). He founded and was Chairman of the Board of Directors of Corvas International, Inc., which was acquired by Dendreon. Dr. Edgington also founded Molecular Biology Consultants Inc., BioSequences Ltd., and NuVas LLC. He served as a director of Apollon, one of the earliest DNA vaccine companies, which was acquired by Wyeth. He also served as a member of the scientific advisory board of Halozyme Therapeutics, Inc.

 

Anthony Ford-Hutchinson, Ph.D.

 Former Senior Vice President, Vaccines R&D, Merck

ANTHONY FORD-HUTCHINSON has over 30 years' experience in vaccine development and commercialization and was formerly at Merck and Co. During his tenure at Merck, Dr. Ford-Hutchinson played a leadership role in the development of several new blockbuster vaccines, including Gardasil®, Zostavax®, Proquad® and Rotateq®. He was also responsible for the development of many important Merck drugs, including Singulair®, Arcoxia® and Isentress® for asthma, pain/inflammation, and the treatment of HIV infection.

Dr. Ford-Hutchinson, who retired from Merck in early 2012, was most recently Senior Vice President, Vaccines Research and Development and Chairman of the Board of Directors for MSD Wellcome Trust Hilleman Labs. He has held many other prominent positions at Merck in Canada and the USA, including Executive Vice President for Worldwide Research. He was responsible for all strategic decisions in Merck's vaccine R&D following appointment as franchise head in 2005, producing a pipeline with three vaccines in phase III trials and a number of others in earlier development. He obtained his Bachelor's degree in biochemistry from the University of Birmingham, a Master's in molecular enzymology from the University of Warwick, and a Ph.D. in biochemistry from the University of London.

Philip D. Greenberg, M.D.

Professor of Medicine & Immunology
University of Washington
Head, Program of Immunology,
Fred Hutchison Cancer Research Center

PHILIP GREENBERG has had a long-standing research career illuminating the principles that underlie T-cell recognition of viruses and cancer cells, determining why such responses often fail to eliminate the viral pathogen or cancer, and developing cellular and molecular approaches to manipulate cellular immunity to treat human viral and malignant diseases.

His current research includes studies in transgenic mice to elucidate the requirements for inducing therapeutically effective T-cell responses to self-proteins that are overexpressed in tumors, development of genetically-modified mice to better model human immune responses to facilitate the development of vaccines for HIV and cancer, genetic modification of T-cells to improve efficacy in adoptive therapy, and clinical trials for the treatment of leukemia with adoptive T-cell therapy.

Dr. Greenberg’s professional awards include the Cancer Research Institute William B. Coley Award for Distinguished Research in Tumor Immunology (2011), which he received jointly with Steven A. Rosenberg, M.D., Ph.D., for their pioneering work in the development of adoptive immunotherapies for the treatment of cancer.

Dr. Greenberg graduated from Washington University with a degree in biology and, in 1971, received his Doctor of Medicine degree, summa cum laude, from the State University of New York, Downstate Medical Center. After completing postdoctoral training at the University of California at San Diego, he joined the Fred Hutchinson Cancer Research Center and the Division of Oncology at the University of Washington in 1976.

 

Stanley A. Plotkin, M.D.

Emeritus Professor, Wistar Institute and University of Pennsylvania
Principal, Vaxconsult

STANLEY PLOTKIN developed the rubella vaccine now used worldwide and has worked extensively on the development and application of other vaccines including polio, rabies, varicella, rotavirus and cytomegalovirus. He is Emeritus Professor, Wistar Institute and the University of Pennsylvania, and is a principal of Vaxconsult.

Over the course of his career he has served as senior assistant surgeon with the Epidemic Intelligence Service of the U.S. Public Health Service; Chairman of the Infectious Diseases Committee and the AIDS Task Force of the American Academy of Pediatrics; Chairman of the Microbiology and Infectious Diseases Research Committee of the National Institutes of Health; director of the Division of Infectious Diseases at Children's Hospital of Philadelphia; associate chairman of the Department of Pediatrics, University of Pennsylvania; medical and scientific director of Aventis Pasteur; and executive advisor to Sanofi Pasteur. Over 600 of his articles have been published, and he has edited several books including Vaccines, now the standard textbook in the field.

Dr. Plotkin's numerous professional awards include:

  • The medal of the Fondation Mérieux (2007);
  • The Fleming (Bristol) Award of the Infectious Diseases Society of America (2004);
  • The Sabin Foundation Medal (2002);
  • The French Legion Medal of Honor (1998);
  • The Clinical Virology Award, Pan American Group for Rapid Viral Diagnosis (1995);
  • The Distinguished Physician Award, Pediatric Infectious Disease Society (1993); and,
  • The Bruce Medal of the American College of Physicians (1987).

Dr. Plotkin earned his M.D. at the State University of New York, Downstate College of Medicine and holds honorary degrees from the University of Pennsylvania and the University of Rouen (France). He serves on the Board of Directors of Dynavax and is Chairman of the Scientific Advisory Board of Mymetics as well as serving as an International Society for Vaccines advisor.